Skip to content
Teethgrinder – Lifestyle
Author:
GENFIT S.A.
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
September 11, 2026
GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
September 9, 2026
GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
September 3, 2026
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
July 8, 2026
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
July 2, 2026
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
June 23, 2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
June 15, 2026
GENFIT: NASHnext®, Powered by GENFIT’s Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 8, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 25, 2026
1
2
Next Page
→